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ABSTRACT 
Cannabidiol (CBD) was administered both ac utely and sub-
acutely to mice, and the resulting effects on hexobarbital sleep 
time and on the hepatic microsomal drug-metabolizing system were 
assessed. Acutely administered CBD significantly prolonged hexo-
barbital sleep tirne, an effect that persisted for as long as 24 hr; 
but following subacute treatment, tolerance rapidly developed to the 
CBD effect. Brain hexobarbital concentration upon awakening vias 
unchanged by either acute or subacute CBD treatment, which sug-
gests that neither the acute effect of CBD on sleep time nor the tol-
erance that develops in subacutely treated animals is the result of a 
central interaction of the drug with the barbiturate. Acute CBD 
treatment increased the half-time of hexobarbital in the brain, evi-
dence that the drug decreased the rate of hexobarbital metabolism. 
Tolerance was acc ompanied by a decrease in the elevated half-time 
of brain hexobarbital, suggesting that tolerance was a consequence 
of a return toward the normal rate of hexobarbital metabolism. 
Acutely administered CBD caused a 30 per cent depression in cyto-
chrome P-450 concentration; the duration of the decline approximated 
the duration of CBDls prolongation effect on sleep time. Follow-
ing subacute treatnlent, cytochrome P-450, total liver protein and 
mlcrosomal protein concentrations were the same as the controls, 
but NADPH -cytochrome ~ reductase activity and liver weight 
increased by about 20 per cent; the latter increases did not repre-
sent a func tionally significant induction of hexobarbital me tabolism. 
The evidence suggests that the CBD-caused prolongation of barbi-
turate sleep tinle is the result of a decrease in the rate of barbi-
turate metabolism related to a decrease in cytochrome P-450 con-
centration. Tolerance to the effect is associated with a return to 
a normal metabolic rate and to normal cytochrome P-450 values. 
v 
ABSTRACT .. 0 
INTRODUCTION .. 
TABLE OF CONTENTS 







. . . . . 2 
o • • • 5 
. 26 
. . . 33 
INTRODUCTION 
Although cannabidiol (CBD) is a major constituent of mari 
huana [1], little is kno\vn about its pharmacological properties. 
Nevertheless, CBD is toxicologically important, precisely because 
it is a maj or constituent of marihuana, and also because the pre-
clinical evaluation of its anticonvulsant properties suggests that the 
drug may be a useful antiepileptic agent [2] 6 The clinical potential 
of the drug is enhanced by its apparent lack of toxicity. In humans, 
CBD, even in nlassive intravenous doses, lacks the characteristic 
psychotoxic and cardiovascular effects of marihuana or A9 -tetrahy-
drocannabinol (A9 -THC) [3]. Animal studies, however, have demon-
strated that CBD can pr olong barbiturate sleep time [4], which was 
subsequently shown to be the result of the cannabinoid1s ability to 
inhibit barbiturate metabolism by the liver [5-7]. Because CBD is 
an inhibitor of hepatic drug metabolism, a potential exists for toxic 
drug interactions with either the illicit or licit use of the drug. The 
following study was de signed to determine the effec ts in mice of 
both acute and subacute CBD treatment on hexobarbital sleep time 
and on the oxidative drug -metabolizing enzyme s in the liver. 
MATERIALS AND METHODS 
Male Charles River mice (ICR) weighing 20-30 g were 
used in all the experiments. CBD was suspended in isotonic 
saline containing 30/0 Tween SOJ as described by Karler et a1. 
[S], and hexobarbital was dissolved in isotonic saline immedi-
ately prior to injection. All drugs were administered intraperi-
toneally. The dose of CBD was 120 mg/kg which represents 
the anticonvulsant EDso in mice in a maximal electroshock 
te s t [9] . 
Hepatic microsomes were prepared by a modification of 
the procedure of Franklin and Estabrook [10]. Livers were 
homogenized in 0.25 M sucrose solution (1:5 J w/vL and the re-
sulting homogenates centrifuged at 20,000 g for 20 min in a 
Beckman L 2 ultracentrifuge. The supernatant fraction was then 
centrifuged at 100,000 .£ for 30 min. The recovered pellet was 
suspended in 1. 150/0 KCl and the suspension was centrifuged at 
100,000 il for 30 min. The pellet was finally resuspended in 0.25 
M sucrose solution containing 50 mM Tris -chloride buffer, 
pH 7.4, to obtain a final protein concentration of approximately 
3 
10 mg/ml. For the metabolic -complex detection experiments, 
only freshly prepared microsomes were used; for all other studies, 
microsomal suspensions were obtained from a frozen stock, which 
was stored for no longer than 4 days. 
All spectral work was performed at room temperature in a 
Cary 118 spectrophotometer. For these studies, microsomes 
were suspended in 50 mM Tris-chloride buffer, pH 7.4, contain-
ing 1. 15% KCl and 10 mM MgCla , to obtain a final protein concen-
tration of 1 mg/ml. Cytochrome P- 450 was measured using an 
extinction coefficient of 91 mM-1cm-1 , as described by Omura 
and Sato [11]. 
For the spectral studies, drugs were prepared as follows: 
An alcoholic solution of Pluronic F68 (BASF Wyandotte Corp. ) was 
mixed with CBD, A9 -THC, or piperonyl butoxide. Nitrogen was 
used to evaporate the ethanol; water was then added to the re sidue 
and the resulting mixture was sonicated in a Branson Sonifier 
W-350. The concentration of Pluronic in the drug stock prepara-
tion was 5 mg/ml and in the microsomal suspensions, 0.1 mg/ml. 
Drug concentrations in the microsomal suspensions were: CBD, 
0.06 mM; AS-THC, 0.13 mM; piperonyl butoxide, 2.4 mM. The 
microsome -drug suspensions were divided into the sample and 
reference cuvettes, and drug-metabolizing reactio'ns were 
4 
initiated by the addition of NADPH (0. 24 mM) to the salnple cuvette 
only. During a 20-min reaction period, samples were monitored 
periodically for complex formation by scanning the 500 -400 nm 
region. 
Microsolnes isolated from CBD-treated mice were 
examined for drug-cytochrome P-450 complexes formed in vivo. 
Ferricyanide oxidation, as de scribed by Buening and Franklin 
[12], was used as a te st for c omplexe s of the SKF 525 -A type. 
In order to detect complexes of the piperonyl butoxide type, the 
microsomes were divided into two cuvettes and the sample cell 
was reduced by the addition of a few crystals of dithionite [13]. 
Cytochrome::. reductase activity was determined by the 
method of Williams and Kamin [14], protein concentrations by the 
method of Lowry [15], and heme determinations as described by 
Omura and Sato [11] and Gilbert [16 ]. Hexobarbital sleep times 
were measured from the loss to the recovery of the righting 
reflex, and brain hexobarbital concentrations were determined 
by the method of Vesell [1 7]. 
RESULTS 
The time course of the prolongation of hexobarbital sleep 
time was determined following a single dose of CBD (Fig. 1). 
Significant increase s in sleep time s were observed for as long as 
24 hr after CBD administration; and the response at 48 hr was 
essentially normal. In subsequent experiments, measurements 
of sleep time were made 4 hr after CBD treatment, because this 
time, associated with a marked effect, was experimentally con-
venient. 
The effect of subacute CBD treatment on sleep time is 
shown in Fig. 2. Mice were given daily doses of CBD for the in-
dicated number of days, and hexobarbital sleep times were 
measured 4 hr after the last dose. Animals ¥'ere used only once 
for a sleep-time determination; therefore, each test time repre-
sented a different group of animals. The results of the repeated 
treatment suggest that tolerance develops to the sleep'-time effect 
of CBD: For example, acutely administered drug prolongs sleep 
time about 2. 5 time s the c ontr 01 value as shown on day 1 in Fig. 
2; but after 6 days of treatment, the sleep time is' only slightly 
6 
Figure 1. Time course of the effect of CBD on hexobarbital sleep 
time. Hexobarbital (IOO mg/kg) sleep time s were measured 1, 4, 
12, 24 and 48 hr after a single dose of CBD (120 mg/kg). Each 
value is expre s sed as the mean and standard deviation of a gr oup 
of 20 animals, and no animals were used more than once. The 
asterisks (~~) indicate the values that are significantly different 
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Figure 1. Time course of the effect of eBD on hexobarbital 
sleep time 
7 
Figure 2. Effect of subacute CBD treatment on hexobarbital 
sleep time. Animals were treated every 24 hr with CBD 
(120 mg/kg) for the indicated number of days. Hexobarbital 
8 
(100 mg/kg) sleep times 'were measured 4 hr after the final treat-
rnent; each treatment group consisted of 13 -1 7 animals and the 
mean and standard deviation for each group are show~n. The data 
were subjected to a regression analysis; the slope of the line is 
-0. 058 and the correlation c oeffic ient is O. 63. The slope is 
significantly different from zero, as determined by a t test 
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Figure 2. Effect of subacute CBD treatment on 
hexobarbital sleep time 
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longer than that of the control. Furthermore, an analysis of the 
data indicate s that the slope of the line in Fig. 2 is ne ga ti ve and 
significantly different from zero (P < 0.01), thus confirming the 
interpretation that tolerance rapidly develops to the effect of CBD 
on hexobarbital sleep time. In subsequent studies of tolerance, 
animals were given CBD daily for 4 days, because this treatment 
period was adequate to produce a measurable degree of tolerance. 
The data in Table 1 were obtained from experiments that 
were designed, in part, to find out whether the CBD-enhanced 
sleep time was the result of an increased sensitivity of the central 
nervous system (CNS) to hexobarbital. The results in Table 1 
show that 4-hr pretreatment with CBD increased sleep time from 
39 min to III min; however, the brain concentration of hexobarbital 
upon awakening was unchanged, which sugge sts that the drug, 
acutely administered, did not interact centrally with the barbiturate. 
The subacutely treated group in this study clearly showed the 
development of tolerance to C BD, as evidenced by the decrease in 
sleep time from III min in the acutely treated to 62 min; the toler-
ance, however, was not accompanied by a decrease in the sensi-
tivity of the CNS to hexobarbital, because, upon awakening, the 
brain concentration of the barbiturate in the subacutely treated 
rnice (38 J.lg/g brain) was not significantly different from that in 
Table 1. Effect of acute and subacute CBD treatn1ent on the 





Brain C oncentratiori:f:: 
Treatment~~ (/-tg/kg 
Control 39 :I: 7~~ 37 :!: 6 
Acute III :I: 14~~ 35 ::!: 8 
Subacute 62 :!: 20* 38 ::!: 7 
:!< Control animals received vehicle for 4 days; acute, 
vehicle for 3 days and CBD (120 mg/kg) on the fourth day; sub-
acute, CBD (120 mg/kg) for 4 days. All measurements were 
made 4 hr after the last treatment. 
t Sleep times were measured following a single i. p. dose 
of hexobarbital (100 rng/kg). Each value repre sents a mean and 
standard deviati on of 15 animals, and all value s are significantly 
different from each other, as determined by the multiple range 
test (P < 0.05). 
':f:: Brain hexobarbital concentration upon awakening was 
determined following a single dose of hexobarbital (100 mg/kg). 
Each value represents a mean and standard deviation of 12 
animals. There are no significant differences between any of 
the values as determined by the multiple range test (P < 0.05). 
12 
the ac utely treated group (35 I-Lg/ g brain). 
The results shown in Fig. 3 illustrate that acute CBD treat-
ment increases the half-time of the barbiturate in the brain fronl a 
control value of 22 min to 53 min; such an effect is indirect evi-
dence that the rate of hexobarbital metabolism is decreased by 
CBD. In the subacutely treated animals the half-time is 33 min, 
which is a significant reduction from the 53 -min half-time in the 
acutely treated group; that is, the barbiturate half-time tends to 
re turn to normal in tole rant animals. 
The above evidence indicates that a likely site of action of 
CBD is the hepatic microsomal drug-metabolizing system; conse-
quently, the drug's effect on cytochrome P-450 concentration was 
investigated (Fig. 4). A single dose of CBD caused a signifi-
cant decline in cytochrome P-450 concentration, an effect which 
lasted for 12 hr after drug administration; the duration of this 
decline approximates that of the effect on sleep time (Fig. 1). 
Such depression in cytochrome P-450 concentration, however, was 
not followed in the recovery period by a greater-than-normal 
cytochrome P-450 concentration; that is, no rebound phenomenon 
was rec orded either at 24 or 48 hr after treatment, sugge sting 
that the rapid development of tolerance doe s not appear to involve 
cytochrome P-450 induction. 
13 
Figure 3. The half-times of hexobarbital in the brain following 
acute and subacute tr eatment with CBD. The acute group re-
ceived vehicle daily for 3 days, CBD the fourth day; the subacute, 
CBD daily for 4 days; and the control, vehicle daily for 4 days. 
The dose of CBD was 120 mg/kg. Four hr after the final treat-
ment, each animal received a single dose of hexobarbital 
(130 mg/kg). Each point represents the mean brain-hexobarbital 
concentrations of 5 animals. The slopes of the lines, determined 
by linear regression analysis, are -0.0.13 for the acute, -0.022 
for the subacute, and -0.031 for the control treatment; the cor-
relation coefficients are in parentheses. The slopes are signifi-
cantly different from each other, as determined by a t test 
(P < 0.05). The half-times of hexobarbital in the brain were 



















Acute CSD (0.72) 






o 10 20 30 40 
TIME (min) 
Figure 3. The half-times of hexobarbital in the brain 
following acute and subacute treatment with CBD 
14 
15 
Figure 4. Time course of the effect of CBD on cytochrome P-450 
concentration. Each animal was given a single dose of CBD 
(120 mg/kg) or vehicle and the concentration of cytochr orne P -45 0 
was determined 1, 4, 12, 24 and 48 hr after drug administration. 
The results are expressed as a percentage of control. The values 
represent means of groups consisting of 9-13 animals; the ranges 
are in parentheses. The mean absolute concentration of cyto-
chrome P-450 in the controls was 0.72 nmoles/mg microsomal 
protein. The asterisks (~~) indicate values that are significantly 
different from their corresponding controls, as determined by 
the Mann-Whitney U test (P < 0.05). 
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Figure 4. Time course of the effect of CBD on 
cytochrome P-450 concentration 
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The in-vitro microsomal metabolism of CBD was studied 
in order to determine whether the decline in cytochrome P-450 
was due to a CBD metabolite-cytochrome P-450 complex. In 
these studies, CBD was compared to A9 -THC {a cannabinoid v/hich 
is not a potent inhibitor of drug metabolism [5-7]} and to piperonyl 
butoxide {a compound which is known to produce metabolic -inter-
mediate complexes with cytochrome P-450 [13]}. CBD, A9 -THC 
and piperonyl butoxide were metabolized in the presence of hepatic 
microsomes and NADPH, and each system was monitored spectro-
photometrically (Fig. 5). Two concentrations of CBD and 
A9 -THC were used in these experiments: one approximately 
eq ual to the Km , and the othe r, 1 0 time s the K for the me tab-m 
olism of the drugs. The spectral data from only the higher 
drug-concentration experiments are shown in Fig. 5, but the 
results from the lower drug concentrations were identical. 
Under these conditions, piperonyl butoxide produced its 
characteristic metabolic -intermediate complex absorption 
spectrunl. with a maximum at 455 nm; however, neither CBD 
nor A9 -THC formed a spectrophotometrically detectable complex 
(Fig. 5A). 
The dithionite reduction of the microsomes following~-
vitro metabolism resulted in the appearance of an absorption 
18 
Figure 5. Spectral analyses of microsomal systems metabolizing 
CBD, ~9-THC and piperonyl butoxide. 
A. Analysis for metabolic -intermediate complexes with cyto-
chrome P-450. Hepatic microsomes were prepared from an 
untreated mouse; microsomal suspensions contained 1 mg 
protein/ml. The concentrations of CBD (0.06 mM) and 
69-THC (0.13 nM) were approximately 10 times the apparent 
KII values for these drugs. The concentration of piperonyl 
butoxide was 2.4 mM. NADPH (0.24 mM) was added only to 
the sample cuvette. After a reaction time of 9 min at room 
temperature, a difference spectrum was obtained 
(500 -400 nm). 
B. Effect of dithionite reduction on the spectral analysis of 
the reaction systems in SA. After a reaction time of 10 min, 
microsomal systems in A were reduced by the addition of 
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Figure 5. Spectral analyses of n1icroson1al systerns metabolizing 
CBD. ~'a_THC and piperonyl butoxide 
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spectrum with a maximum at 450 nn1. (Fig. 5B). This result was 
uniquely associated with the CBD system and not with either 
AS-THC or piperonyl butoxide. The appearance of cytochrome 
P-450 suggested that CBD metabolism endogenously generated 
carbon monoxide; and, in fact, the complex was dissociated by 
bubbling the cuvette with oxygen. The apparent generation of 
carbon monoxide was also sho\vn to require CBD metabolism; 
that is, a non-metabolizing system containing only CBD and 
microsomes did not cause the appearance of the cytochrome P-450 
absorbance. Moreover, the data indicate that the source of the 
carbon monoxide is not the enzymic destruction of cytochrome 
P -450, because the concentration of P-450 did not change during 
the in-vitro metabolism of CBD; both initial and final concentra-
tions of cytochrome P-450 (before and after 1 O-min incubation) 
were 0.6 nmoles/mg protein. 
Fig. 4 shows that in acutely treated animals CBD caused 
a decrease in cytochrome P-450; in order to determine if such 
decrease in vivo was due to a reduction in the available cytochrome 
P-450 by the formation of a metabolite cOll1.plex, the follo\\fing 
experiment was perforll1.ed; Animals were given a single dose of 
CBD and their livers were rell1.oved 4 hr later, at which time a 
significant in-vivo depression in the concentration of cytochroll1.e 
21 
P-450 was recorded (Fig. 4). Microsomes prepared from these 
livers were divided into two cuvettes and one cell was either 
oxidized with ferricyanide or reduced with dithionite. The cells 
were spectrophotometrically scanned in the 500-400 range, and 
no complex formation was revealed. The observed decrease in 
cytochrome P-450 cannot, therefore, be attributed to the presence 
of complexes of the SKF 525 -A and piperonyl butoxide types. 
An attempt was also made to discover whether the decline 
in cytochrome P-450 was reflected by a decrease in total micro-
somal heme content: Total heme was measured in 12 control and 
12 CBD treated animals 12 hr after drug administration. The 
mean and standard deviation of the c ontr 01 gr oup was 1. 2 ± O. 17, 
compared with 1. 1 ± 0.14 nmoles/mg microsomal protein for the 
drug-treated group. These values do not differ statistically; 
similar results were obtained 1 hr after drug administration. 
The data on the half-time of brain hexobarbital in Fig. 3 
suggest that the tolerance observed in subacutely treated anirnals 
involves either a reversal of the inhibitory effect, or a compensa-
tory increase in the activity (induction) of the microsomal enzyme 
system. In order to test the latter possibility, a deterlnination of 
the influence of acute and subacute CBD treatment on some hepatic 
constituents was essayed (Table 2). In these experiments, mice 
22 
Table 2. Effect of acute and subacute CBD treatment on the 1iver~:' 
0/0 Control 
Control Acute Subacute 
Liver weightt 100 12 r* 
(84 -113) (107 -1 39) 
Liver protein/g liver t 100 102 
(93-105) (86-115) 
Microsomal protein/ 100 113 
g liver t (78-119) (91-146) 
Cytochr Olne P-450/g 100 78'* 99 
microsomal protein * (77-137) (57-86) (81-135) 
Cytochrome ~ reductase/ 100 99 11 7* 
g microsomal protein * (85-112 (85 -114) (98-157) 
* Control group :::-eceived vehicle daily for 4 days; acute, 
vehicle daily for 3 days and CBD on the fourth day; subacute, 
CBD daily for 4 days. Each value is expressed as a percentage 
of the control and represents a mean of 8-12 animals; the 
range of each value is in parentheses. The absolute mean 
values for the control group are: liver, 1. 7 g; liver protein, 
263 mg/g liver; microsomal protein, 13 mg/g liver; cytochrome 
P-450, 0.77 nmoles/mg microsomal protein; and cytochrome 
~ reductase activity, 77 nmo1es/min/mg microsomal protein. 
t Determined 24 hr after the last treatment. 
'* Value is significantly different fron1. control, as 
determined by the Mann-Whitney U test (P < O. 05). 
$ Determined 4 hr after the last treatment. 
23 
were treated with CBD once (acute) or daily for 4 days (subacute). 
Twenty-four hr after the last dose of CBD, liver weight increased 
significantly by 21 per cent; however, the concentrations of liver 
protein and microsomal protein were unaffected, which suggests 
that the increase in liver weight is a consequence of an increase 
in the nUlTIber of hepatic cells and not a change in the cOlTIposition 
of the existing cells. The hepatic lTIicrosolTIal content of cyto-
chrolTIe P-450 and cytochrolTIe ~ reductase was lTIeasured in another 
group of anin1als 4 hr after the final dose of CBD: Acute CBD 
treatlTIent pI' oduced a significant 22 per -cent decline in cytochr OlTIe 
P-450 concentration, but in the subacute group there was no effect 
on the cytochrolTIe, pointing to a development of tolerance. Cyto-
chrolTIe c reductase results were the reverse of those for cyto-
chrome P-450; that is, in acutely treated animals there was no 
change in the activity of the reductase; however, in the subacutely 
treated group the activity was elevated significantly by 1 7 per cent. 
The above lTIeasurelTIents in tolerant anilTIals revealed only 
two possible signs of lTIicrosolTIal induction: an increase in liver 
weight and in cytochrolTIe ~ reductase activity. The functional 
significance of the se change s in terlTIS of hexobarbital sleep tilTIe 
was lTIeasured in tolerant animals. The data shown in Table 3 
were obtained fr om animals treated daily with CBD for the 
Table 3. Influence of daily CBD administration 
on hexobarbital sleep time 
Days of Treatment Sleep Timet.\: 
Vehicle CBD 
1 26:f: 8 44 :f: lOt 
2 20 :f: 5 3l:f: 10 
4 1 9 :f: 7 20 :f: 6 
8 2l:f: 6 30 :f: 8 
12 2 1 :f: 5 32 :f: 7 
12* 29 :f: 9 32 :f: 6 
* Hexobarbital (IOO mg/kg i. p.) sleep time s 
in groups 1 through 12 were measured 24 hr after 
the final CBD treatment (120 mg/kg/day). All 
sleep-time values represent means and their 
standard deviations of oups of 20 mice. Each 
group was tested for sleep time once only. 
t Value is significantly different from control 
as determined by a t test (P < O. OS). 




indicated number of days, and hexobarbital sleep times were deter-
mined either at 24 or 48 hr after the last dose of CBD. For as long 
as 12 days of daily CBD treatrnent, there was no reduction in 
hexobarbital sleep time; therefore, the CBD tolerance cannot be 
ascribed to a functionally significant induction of the hexobarbital-
metabolizing enzymes. 
DISCUSSION 
The ability of CBD to inhibit hepatic drug metabolism 
poses a toxic potential in terms of drug interactions, whether the 
drug is used for licit or illicit purposes. The dose of CBD in 
illicit usage is several orders of magnitude lower than that of the 
present study, and the work of Dalton et al. [18] suggests that 
the relatively low doses derived from marihuana do not affect 
secobarbital metabolism in humans. Because of the interest in 
CBD as an antiepileptic agent, the principal goal of the present 
study was to determine and define some of the characteristics 
of the interaction between anticonvulsant doses of CBD and the 
hepatic microsomal drug-metabolizing enzymes. The dose of 
CBD selected for the investigation, 120 mg/kg, is the anticonvul-
sant ED50 for mice in a maximal electroshock test [9]. The 
in-vivo drug-n1.etabolzing activity was assessed in terms of 
hexobarbital sleep time because hexobarbital is primarily metab-
olized by the hepatic microsomal enzymes [19] and the sleep 
time is proportional to the activity of these enzymes [17]. 
Acutely administered CBD was shown to prolong 
27 
significantly hexobarbital sleep time in mice for 24 hr, an effect 
similar to that described by Paton and Pertwee [5]. There appear, 
however, to be species differences in the duration of CBD's sleep-
time effect: For example, Siemens et al. [7] reported that can-
nabis extracts enhanced pentobarbital sleep time in the rat for as 
long as 63 hr after drug adm.inistration. Regardless of these 
species differences, the mechanism of the inhibiton appears to be 
the same. Previous studies with lower CBD doses (10 mg/kg) 
demonstrated that the prolongation of barbiturate sleep time is not 
the result of a central interaction between CBD and the barbiturate, 
but the consequence of CBD's ability to inhibit barbiturate metab-
oHsm by the liver [4-6J. These conclusions were also found to be 
valid for the relatively high doses of CBD used in the present 
study. The concentration of hexobarbital in the brain upon awaken-
ing was unchanged foll owing acute CBD treatment, indicating that 
the drug did not alter the sensitivity of the CNS to the barbiturate. 
Furthermore, the treatment increased the half -tim.e of hexobarbi-
tal in the brain, indirect evidence that CBD decreased the rate of 
hexobarbital metabolism. 
In the subacute experiments, tolerance rapidly develoPed 
to the CBD effect on hexobarbital sleep time, and associated with 
the tole rance was a return of the hexobarbital half -time in brain 
28 
toward the control values. The decrease in hexobarbital ha1f-
time may result from an increased rate of drug metabolism, and 
the possibility that tolerance is of the dispositional, rather than 
the cellular, type is further bolstered by the failure of subacute 
CBD treatment to change the brain concentration of hexobarbital 
upon awakening; in other words, the tolerance was not related to 
an alteration in the sensitivity of the CNS to the barbiturate. 
The above findings imply that both the acute and subacute 
effects of CBD involve the hepatic drug-metabolizing system. An 
investigation of the effect of CBD on this system revealed that a 
single dose of CBD caused a significant depression in cytochrome 
P-450 concentration, an observation of particular interest because 
the cytochrome has been implicated as the site of action of two 
other inhibitors of drug metabolism, SKF 525 -A and piperony1 
butoxide; that is, both of these compounds are believed to inhibit 
drug metabolism by inactivating cytochrome P-450 [12, 13]. In 
addition, the magnitude and duration of the CBD-induced decline 
in cytochrome P-450 concentration was similar to that produced 
by SKF 525 -A. 
The decrease in the concentration of cytochrome P-450 
may account for CBD
' 
s inhibitory effect on hexobarbital metabo-
lism. This conclusion is supported by the evidence that the 
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duration of the cytochrOITle P-450 decline following acute CBD 
treatment approximates the duration of the sleep-time prolonga-
tion, about 24 hr. Furthermore, following subacute CBD treat-
ment, the cytochrome P-450 concentration is restored to the 
normal value; therefore, animals that are tolerant to the effect 
of CBD on sleep time are also tolerant to the drug's action on 
cytochrome P-450. 
Levin et al. [20] reported that the degradation of cyto-
chrome P-450 in the rat is a biphasic process, with a half-time 
of 7-8 hr for the fast and 42-46 hr for the slow phase. CBD's 
depression of cytochrome P-450, which has a rapid onset, could 
possibly be the result of inhibition of the synthesis of the cyto-
chrome; however, the above suggestion is only plausible if most 
of the cytochrome P-450 in the mouse were very rapidly degraded. 
Since the degradation rate in the mouse is not known, two other 
possible mechanisms of the decline in cytochrome P-450 were 
considered: Either eBD could promote the destruction of the 
cytochrome or it could interfere with its spectral detection. The 
metabolism of CBD was studied in order to distinguish between 
these two alternatives. 
SKF 525 -A and piper onyl butoxide form metabolic -inte r-
mediate complexes with cytochrome P-450 which prevent carbon-
monoxide binding and, thereby, reduce the amount of spectrally 
measurable cytochrome P-450 [12) 13]. The complexes them-
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selves have characteristic absorption maxima that can be detected 
in microsomes following both in-vivo and in-vitro metabolism of 
these drugs. In contrast, the in-vivo administration of CBD did 
not yield a spectrally detectable complex, although there was a 
significant in-vivo decline in cytochrome P-450 at the time of the 
measurement. Moreover, no complex absorption maxima and no 
decline in spectrally measurable cytochrome P-450 were seen 
after the in-vitro metabolism of either relatively low (Km) or high 
(10 times Km) concentrations of CBD, even though the high concen-
tration (0.06 mM) was probably sufficient to inhibit non-competi-
tively hexobarbital metabolism in vitro [6] . 
Because the recorded in-vivo decrease in cytochrome 
P-450 cannot be accounted for by complex formation, the decrease 
may be a consequence of a destruction of cytochrome P-450. Such 
an effect has been reported for many other drugs, including allyl-
isopropylacetamide and secobarbital [21, 22]. A change in the 
absolute amount of cytochrome P-450 could be determined by 
quantitating total herne. Such an assessment, however, failed to 
detect any significant decrease in total microsomal heme concentra-
tion. 
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As described earlier, repeated CBD treatment is accom-
panied by a restoration of the normal rate of hexobarbital metab-
olism, which is indicative of a development of tolerance. Such 
tolerance may be due either to a reversal of the inhibitory action 
of CBD or to a compensatory increase in the activity of the 
microsomal enzyme system. For example, SKF 525-A has been 
shown to induce the activity of the hepatic microsomal system 
[23, 24], and Buening and Franklin [12] demonstrated that 
repetitive treatment produced a marked increase in the concentra-
tion of cytochrome P-450. In order to determine whether CBD 
tolerance is the result of induction, the influence of subacute 
CBD on sonle constituents of the drug-metabolizing system was 
assessed. Unlike SKF 525-A, subacute CBD treatment does not 
increase the cytochrome P-450 concentration; in addition, micro-
somal protein per g liver and liver protein per g liver remained 
unchanged. The only signs of induction were an increase in cyto-
chrome ~ reductase activity and in total liver weight. Following 
CBD withdrawal after 12 days of daily treatment, however, sleep 
time was normal; therefore, CBD tole,rance cannot be ascribed to 
a functionally significant induction of the hexobarbital-metabo-
lizing enzyrnes. 
Generally speaking, the results of the present study are 
consistent with other investigators' findings that CBD prolongs 
sleep time by inhibiting the hepatic drug-metabolizing system. 
Although the precise mechanisn1. of CBD' s inhibitory ac tion is 
still unknown, it does appear that the depression of cytochrome 
P-450 may account, at least in part, for CBD's effect on drug 
metabolism. Finally, the rapid development of tolerance to the 
inhibitory effect of CBD may serve to minimize potentially toxic 
drug interactions arising from chronic exposure to the drug. 
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